A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/rodney-prell

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Rodney Prell

Staff Scientist, Toxicology, Safety Assessment

"It has been a privilege to work in Safety Assessment at Genentech, where we take patient safety as our highest priority."

Years at Genentech

I received my PhD and postdoctoral training in immunotoxicology and cancer immunotherapy, respectively. I joined Genentech as a scientist/toxicologist in 2007 after six years of cancer immunotherapy pharmacology and toxicology research in small biotech in the San Francisco Bay Area. My initial responsibilities were mainly as a project team toxicologist where I designed and implemented non-clinical safety studies to support INDs through BLAs. I am currently a Staff Scientist/Toxicologist and Safety Assessment Therapeutic Area Lead for Cancer Immunology, where I have oversight for the safety assessment strategy for the Cancer Immunology portfolio. I am a Diplomat of the American Board of Toxicology (DABT) since 2004.

Featured Publication

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.

Int J Toxicol 2016 35(3): 263-273.

Prell, R.A., Halpern W.G. and Rao, G.

View Abstract

My focus area is the safety assessment of new molecular entities in cancer immunology. This area spans a wide variety of platforms and modalities and as such, requires flexible approaches for nonclinical safety to support first in human studies and appropriate first in human dose selection. We are exploring ways to improve the existing or develop novel nonclinical safety models support cancer immunology drug development.

Oregon State University, Ph.D. Toxicology Program (Immunotoxicology) – 1997
University of Wisconsin-Madison, Biochemistry, B.S. – 1989

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Rodney Prell

Staff Scientist, Toxicology, Safety Assessment

Featured Publication

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

A link to this page has been copied to your clipboard.

Rodney Prell

Staff Scientist, Toxicology, Safety Assessment

Featured Publication

Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy.